Best Deals on Prescription Weight Loss Meds for New Patients in 2026
Brand-name GLP-1 pills from $149/month. Compounded injectables from $146/month. Manufacturer savings programs, Medicare expansion, and every other way to start treatment at the lowest possible cost.
GLP-1 weight loss medications used to be exclusively a $1,000+/month proposition. In 2026, that's no longer the case. New oral options, manufacturer savings programs, and an expanding telehealth ecosystem have pushed entry-level pricing below $150/month for the first time.
If you're starting treatment in 2026, here's what every option actually costs — ranked by price, with no guesswork.
Tier 1: Under $200/Month
These are the most affordable ways to start GLP-1 treatment right now. Each option includes the medication itself and, in most telehealth cases, the medical consultation.
| Option | Type | Monthly Cost | Notes |
|---|---|---|---|
| Oral Wegovy (starting dose) | Brand-name pill | $149/mo | FDA-approved, via NovoCare pharmacy |
| Foundayo / orforglipron (starting dose) | Brand-name pill | $149/mo | FDA-approved April 2026, via LillyDirect |
| Yucca Health (6-month plan) | Compounded injectable | $146/mo (sema) | Multi-month commitment required |
| Care Bare Rx | Compounded injectable | from $199/mo | Includes consultation, streamlined intake |
Semaglutide and tirzepatide programs with transparent multi-month pricing. One of the lowest per-month costs available.
Semaglutide from $146/mo (6-mo plan)
⚠️ Compounded medications are not FDA-approved. Paid link.
Direct intake GLP-1 programs with personalized treatment plans and ongoing clinical support.
Starting from $199/mo
⚠️ Compounded medications are not FDA-approved. Paid link.
Tier 2: $200–350/Month
This is where most telehealth providers with compounded GLP-1 programs land. These options typically bundle the consultation, prescription, medication, and shipping into a single monthly fee.
| Provider | Type | Monthly Cost | Notes |
|---|---|---|---|
| Eden Health | Compounded injectable | from $239/mo | Direct intake, semaglutide programs |
| Sprout Health | Compounded injectable | Post-consultation | Pricing disclosed after medical intake |
| SHED | Compounded injectable | from $297/mo | Comprehensive program; price increases at 7.5mg+ |
| Oral Wegovy (maintenance dose) | Brand-name pill | $199–299/mo | Higher doses cost more via NovoCare |
| Yucca Health (tirzepatide) | Compounded injectable | from $258/mo | 6-month plan pricing |
GLP-1 semaglutide programs with direct intake and personalized treatment plans.
Semaglutide from $239/mo
⚠️ Compounded medications are not FDA-approved. Paid link.
Comprehensive GLP-1 weight management with licensed providers and home delivery.
Starting from $297/mo
⚠️ Compounded medications are not FDA-approved. SHED pricing increases at doses of 7.5mg and above. Paid link.
Tier 3: Brand-Name With Insurance
If your insurance covers GLP-1 medications for weight management, this is almost always the cheapest path — but prior authorization requirements remain common.
| Scenario | Estimated Monthly Cost |
|---|---|
| Commercial insurance with GLP-1 coverage | $0–100 copay |
| Medicare BALANCE Model (launching 2026–2027) | ~$50 capped copay |
| Medicaid (varies by state) | $0–25 copay |
| No insurance, retail cash-pay | $499–1,300/mo |
Step 1: Check your formulary. Contact your insurance provider and ask whether they cover Wegovy, Zepbound, or Foundayo for weight management (not just diabetes). Many commercial plans have added coverage in 2025–2026 as clinical evidence for cardiovascular and metabolic benefits has expanded.
Step 2: If you're cash-pay, compare oral options ($149/month starting dose for either Wegovy pill or Foundayo) against telehealth providers offering compounded injectables. Both fall in a similar price range at entry level.
Step 3: If you're on Medicare, the BALANCE Model announced by CMS in December 2025 will cap GLP-1 copays at approximately $50/month for qualifying beneficiaries. Medicaid rollout is expected as early as mid-2026, with Medicare Part D coverage starting January 2027.
Brand-Name Direct Consultation
Affordable direct care platform — book a GLP-1 consultation with a licensed clinician for FDA-approved brand-name medications.
Consultations from $99
Paid link.
What's New in 2026
Foundayo (orforglipron) — FDA approved April 1, 2026. Eli Lilly's oral GLP-1 pill is the first that can be taken at any time of day, with or without food, and without water restrictions. Starting price: $149/month via LillyDirect. Available at retail pharmacies beginning April 6, 2026. This is a meaningful new option for patients who prefer pills over injections.
Oral Wegovy — available since January 2026. Novo Nordisk's daily semaglutide pill, FDA-approved December 22, 2025, starts at $149/month for the initial dose through NovoCare pharmacy.
Manufacturer savings programs have expanded. Both Novo Nordisk and Eli Lilly now offer direct-to-consumer pricing that bypasses traditional pharmacy benefit managers, making cash-pay access significantly more affordable than even a year ago.
GLP-1 treatment in 2026 can cost as little as $146–149/month, depending on whether you choose a compounded injectable on a multi-month plan or a brand-name oral option at its starting dose. The days of $1,000+ being the only entry point are definitively over. Your best deal depends on insurance status, preference for pills vs. injections, and whether you want brand-name or compounded.
Sources
- Eli Lilly. FDA approves Foundayo (orforglipron). Press release, April 1, 2026. investor.lilly.com
- FDA. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026. fda.gov
- NJ Bariatric Center. Oral Wegovy pricing and availability. December 2025. njbariatriccenter.com
- CMS. BALANCE Model announcement: expanding GLP-1 access through Medicare and Medicaid. December 2025. cms.gov
Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection. We recommend providers based on verified availability and patient access.